CSSi LifeSciences


CSSi LifeSciences is a global, innovative regulatory consulting group specializing in advancing therapeutics and medical devices through development and regulatory approval. The company offers customized solutions that mitigate risk, time, and expense to support the U.S. market goals of its clients, ensuring a clear and actionable pathway to successful commercialization.

CSSi LifeSciences

CSSi LifeSciences

6751 Columbia Gateway Dr, Suite 300, Columbia, MD 21046, United States


What We Do

Customized strategic and innovative regulatory solutions to navigate the complex regulatory environment for drugs and medical devices.

Comprehensive suite of services to help international life science companies transition to the U.S. market and understand FDA regulations.

Full range of services across all phases of drug and medical device development, from regulatory affairs to clinical trials and market access.

Integrated project management services to support drug and medical device development from discovery to commercialization.

Strategic pathway and consulting services for drug development, including health authority meetings and submission services.

Regulatory solutions for medical devices, including consulting, planning, and submission services.



Key People

Jim Sergi

President

LinkedIn

Ernesto Chanona, Ph.D.

VP of Business Development & Alliance Management

LinkedIn

Heidi Nelson-Keherly, Ph.D.

VP of Drug Development

LinkedIn

John Gustin, Ph.D., MBA

VP of Operations

LinkedIn

Ken Rose, BS

Executive Director, Preclinical Regulatory Affairs

LinkedIn

Diane Markesich, Ph.D.

Director, Translational Research

LinkedIn

News & Updates

Join CSSi LifeSciences at the Annual Partnering Forum during the J.P. Morgan Healthcare Conference from January 8-11, 2024.

Published November 26, 2024, this article discusses the partnership between Trifermed and CSSi LifeSciences to enhance healthcare innovation access.

Published April 18, 2024, this article highlights CSSi LifeSciences' partnership with Jaunt to improve market access for MedTech innovations.

Successful FDA Submissions

CSSi LifeSciences has achieved a 100% success rate with on-time Investigational New Drug (IND) application submissions and over 250 FDA CDRH Class 1 and 2 medical device submissions.

FDA Special Designations

The company has been granted over 30 FDA Special Designations, showcasing its expertise in navigating regulatory pathways.